BioClinica announced that Grünenthal has signed a global license agreement for BioClinica OnPoint CTMS to support its ongoing clinical trials. BioClinica OnPoint CTMS helps clinical trial sponsors to easily consolidate their data, share this data and improve trial management by using Microsoft SharePoint 2010 and Microsoft Office 2010.
Grünenthal selected BioClinica OnPoint after a thorough evaluation of the leading enterprise-scale CTMS solutions. The assessment team was comprised of Grünenthal experts from various functional areas. The workshops demonstrated that the requirements specified by Grünenthal could be delivered faster and most cost-effectively using OnPoint. Grünenthal was particularly impressed with BioClinica’s ability to integrate with other clinical systems, the extensibility of this consolidated data via SharePoint-based dashboards and the fact that OnPoint allows clinical staff to do much of their work within the familiar environment of Microsoft Office applications.
“After careful review of the commercially available CTMS solutions, we felt that BioClinica’s platform provides our clinical staff with a timely and comprehensive overview of relevant data and thus helps to make planning more efficient,” said Hazel Collie, Head of Quality & Systems at Grünenthal. “In this regard, OnPoint supports our objective to enhance our innovation process, allowing us to develop solutions to improve the quality of life of our patients.”
"Life sciences companies of all sizes face increased pressure to efficiently manage clinical trials while bringing drugs to market quickly," said Andrea McGonigle, managing director, Life Sciences, Microsoft Corp. "BioClinica uses Microsoft SharePoint and Office to help clients gain a comprehensive, real-time view into trial performance and act on that information."
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Gilead Shares Final Data from Phase III MYR301 Trial of Bulevirtide in Chronic Hepatitis Delta Virus
May 7th 2025Long-term results from the study show 90% of patients with chronic HDV who achieved undetectable HDV RNA at 96 weeks of treatment remained undetectable for nearly 2 years post-treatment.